Anti-cytokine therapies in chronic heart failure: is this concept still alive?
Parissis
John T
JT
Second Department of Cardiology, Attikon University Hospital, Athens, Greece. jparissis@yahoo.com
Kourea
Kalliroy
K
Kremastinos
Dimitrios
D
D015415:Biomarkers / Q000097:blood; D002908:Chronic Disease; D016207:Cytokines / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D000068800:Etanercept; D005260:Female; D006333:Heart Failure / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D008297:Male; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D016019:Survival Analysis; D016896:Treatment Outcome
D015415:Biomarkers; D016207:Cytokines; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept